# The Clinical Effects of Metronidazole Vaginal Effervescent Tablets Combined with Kushen Suppository in the Treatment of Trichomonas Vaginitis

Authors: Hongxia Zhang; Zeng Jing; Feng Li; Benming Yue; Ping Zhang; Hui Li
Journal: Evidence-Based Complementary and Alternative Medicine
 (2022)

---

## Abstract

Objective. The aim of this study was to explore the clinical effects of metronidazole vaginal effervescent tablets combined with Kushen suppository in the treatment of Trichomonas vaginitis. Methods. Ninety patients with trichomoniasis admitted to our hospital from January 2019 to January 2020 were prospectively analyzed and randomly divided into a control group (n = 45) treated with metronidazole vaginal effervescent tablets and an experimental group (n = 45) treated with Kushen suppository on top of the control group using the random number table method. The clinical effects, inflammatory factors, and microcirculation indexes were compared. We assessed patient’s vaginal health by Vaginal Health Score Scale (VHS) before and after treatment and estimated their quality of life according to Generic Quality of Life Inventory-74 (GQOLI-74). A follow-up visit was conducted to compare patient’s recurrence 3 months after treatment. Results. Distinctly higher total clinical effective of the experimental group compared with that of the control group was obtained (P<0.05); the serum level of inflammatory factors of the experimental group was dramatically lower than that of the control group after treatment (P<0.001); the experimental group experienced a favorable microcirculation index in comparison with the control group (P<0.001); superior VHS (P<0.001) and GQOLI-74 (P<0.05) scores of the experimental group after treatment compared to those of the control group were observed; the recurrence rate of the experimental group 3 months after treatment was significantly decreased in comparison with that of the control group (P<0.05). Conclusion. Metronidazole vaginal effervescent tablets combined with Kushen suppository can effectively improve the clinical symptoms of patients with trichomonas vaginitis, abate patient’s inflammatory reaction, and raise their quality of life, which is worthy of promotion.


---

## Body

## 1. Introduction

Trichomonas vaginitis, as a common gynecological disease, is the female vaginal infection on account ofTrichomonas vaginalis, wherein clinical symptoms will appear such as mucosal redness, swelling, pruritus vulvae, and painful intercourse [1–3]. Unsafe sexual practices and long-term use of antibiotics are thought to be closely associated with the causative factors of this disease [4, 5]. According to relevant data, there are 1.8 billion cases of trichomoniasis worldwide each year, most of which are among people with low immunity and poor lifestyle habits. If patients do not take timely and effective treatment, trichomoniasis can lead to a variety of complications such as cystitis, trichomoniasis urethritis, and pyelonephritis, seriously affecting their physical and mental health and quality of life. At present, medication is the main clinical treatment, which aims to ameliorate patient’s clinical symptoms and restrain disease progression. Among them, metronidazole vaginal effervescent tablets are commonly used drugs in clinic which do have a certain clinical effect but is impotent to disordered vaginal microecological environment, leading to increased drug resistance of patients and the recurrence of disease with the extension of treatment time [6, 7].Bitter ginseng root contains bitter ginseng alkaloids and chrysophanes, which are used to clear heat and dampness, antibacterial, anti-inflammatory, stomachic, and anthelmintic effects, commonly used to treat itchy skin, neurasthenia, indigestion, and constipation. Kushen suppository is mainly used for the treatment of cervical erosion, red and white leucorrhoea, vaginal trichomoniasis, or gynecological inflammation caused by mycobacterial infection. It has anti-inflammatory and antipruritic properties. Animal studies have confirmed that the application of Kushen suppository can lead to a reduction or disappearance of inflammation, as well as a relief of the resulting itching. It should not be used in women with severe allergies or in menstruating patients, except during pregnancy. Clinical research shows that the introduction of Kushen suppository based on this treatment can effectively promote patient’s clinical indicators and has a marked improvement on trichomonas vaginitis [8, 9]. Trichomoniasis is mainly treated with medication, the main western drugs being metronidazole and tinidazole. As patients may have concurrent infections in the urethra, paraurethral glands, and vestibular glands, purely local medication is not easily cured completely, and concurrent systemic medication is required. In view of this, 90 patients with trichomoniasis admitted to our hospital from January 2019 to January 2020 were selected for this study to analyze the efficacy of metronidazole vaginal effervescent tablets combined with Kushen suppository in the treatment of trichomoniasis.


## 2. Materials and Methods

### 2.1. General Information

Ninety patients with trichomoniasis admitted to our hospital from January 2019 to January 2020 were recruited for a prospective analysis and randomly divided into an experimental group (n = 45) and a control group (n = 45) using a random number table hair. The experiment was approved by the ethics committee of The Fourth Hospital of Shijiazhuang for implementation, Approval no. 29791-03.


### 2.2. Inclusive Criteria

The inclusion criteria were as follows: ① no vaginal or uterine surgery; ② no history of psychiatric illness or confusion; and ③ meets diagnostic criteria forTrichomonas vaginalis [10]. This study was approved by the hospital ethics committee, and the family members of the patient have full understanding of the research process and sign the consent form.


### 2.3. Exclusive Criteria

The exclusion criteria were as follows: ① patients combined with mycoplasma and other pathogens infection; ② drug allergy; and ③ those who have used antibiotics or glucocorticoids within one month.


### 2.4. Methods

In the control group, metronidazole vaginal effervescent tablets (Manufacturer: Hubei Dongxin Pharmaceutical Co., Ltd; State Drug License No. H20067252; Specification: 0.2 g/7 tablets/2 plates) were given once or twice a day for seven days. During the medication period, it is important to prohibit sexual intercourse for the time being and keep the vulva clean and dry. Individuals may experience a burning sensation, which may vary in intensity and will disappear after discontinuation of the drug.The experimental group was treated with Kushen suppository (Manufacturer: Guangdong Luofushan National Pharmaceutical Co., Ltd; National Medicine Permission Number Z20063889; Specification: 1.5 g∗6 capsules) based on the control group, administrated vaginally at a dose of 1 capsule per time, once daily. Both group were treated for 15 days.


### 2.5. Outcome Measures

We compared the clinical efficacy of the two groups. Effective: patients’ clinical symptoms such as vulvar itching disappeared and vaginal cleanliness was within I-II degree; totally clinically effective: patients’ clinical symptoms reduced and vaginal cleanliness was II degree; ineffective: clinical symptoms did not improve or even worsened and vaginal cleanliness was III degree. Total clinically effective = significant + effective.Blood was collected from the patient’s fasting elbow vein in the morning. The serum was separated after centrifugation and the supernatant was taken. All serum samples were placed at −80°C. The determination of tumor necrosis factor-α (TNF-α), interleukin 8 (IL-8), and interleukin 1β (IL-1β) in the samples was carried out in strict accordance with the ELISA kit instructions and protocols.The blood perfusion, erythrocyte aggregation, and the diameter of capillary of microcirculation indexes before and after treatment of the two groups were detected by a microcirculation microscope (Manufacturer: Xuzhou Tongren Medical Electronic Technology Co., Ltd; Model: tr8000).The Vaginal Health Scale (VHS) [11] was used to evaluate the vaginal health status of patients into five factors: pH, discharge, vaginal elasticity, moisture, and vaginal mucosa. The total score is 20 points. The higher the score, the healthier the vagina.Quality of life after the intervention was assessed according to theGeneral Quality of Life Inventory 74 (GQOLI-74) [12], which scores four aspects of psychological functioning, physical functioning, social functioning, and physical living status. The total score is 100 points. The higher the score, the better the quality of life.Recurrence was recorded in both groups at a 3-month follow-up observation after treatment.


### 2.6. Statistical Analysis

All data analysis was done by SPSS20.0, and the graphics were plotted by GraphPad Prism 7 (GraphPad Software, San Diego, USA). The counting data and measurement data were examined byχ2 test, t-test, and normality test. A P value of 0.05 or lower was claimed as statistically significant.


## 2.1. General Information

Ninety patients with trichomoniasis admitted to our hospital from January 2019 to January 2020 were recruited for a prospective analysis and randomly divided into an experimental group (n = 45) and a control group (n = 45) using a random number table hair. The experiment was approved by the ethics committee of The Fourth Hospital of Shijiazhuang for implementation, Approval no. 29791-03.


## 2.2. Inclusive Criteria

The inclusion criteria were as follows: ① no vaginal or uterine surgery; ② no history of psychiatric illness or confusion; and ③ meets diagnostic criteria forTrichomonas vaginalis [10]. This study was approved by the hospital ethics committee, and the family members of the patient have full understanding of the research process and sign the consent form.


## 2.3. Exclusive Criteria

The exclusion criteria were as follows: ① patients combined with mycoplasma and other pathogens infection; ② drug allergy; and ③ those who have used antibiotics or glucocorticoids within one month.


## 2.4. Methods

In the control group, metronidazole vaginal effervescent tablets (Manufacturer: Hubei Dongxin Pharmaceutical Co., Ltd; State Drug License No. H20067252; Specification: 0.2 g/7 tablets/2 plates) were given once or twice a day for seven days. During the medication period, it is important to prohibit sexual intercourse for the time being and keep the vulva clean and dry. Individuals may experience a burning sensation, which may vary in intensity and will disappear after discontinuation of the drug.The experimental group was treated with Kushen suppository (Manufacturer: Guangdong Luofushan National Pharmaceutical Co., Ltd; National Medicine Permission Number Z20063889; Specification: 1.5 g∗6 capsules) based on the control group, administrated vaginally at a dose of 1 capsule per time, once daily. Both group were treated for 15 days.


## 2.5. Outcome Measures

We compared the clinical efficacy of the two groups. Effective: patients’ clinical symptoms such as vulvar itching disappeared and vaginal cleanliness was within I-II degree; totally clinically effective: patients’ clinical symptoms reduced and vaginal cleanliness was II degree; ineffective: clinical symptoms did not improve or even worsened and vaginal cleanliness was III degree. Total clinically effective = significant + effective.Blood was collected from the patient’s fasting elbow vein in the morning. The serum was separated after centrifugation and the supernatant was taken. All serum samples were placed at −80°C. The determination of tumor necrosis factor-α (TNF-α), interleukin 8 (IL-8), and interleukin 1β (IL-1β) in the samples was carried out in strict accordance with the ELISA kit instructions and protocols.The blood perfusion, erythrocyte aggregation, and the diameter of capillary of microcirculation indexes before and after treatment of the two groups were detected by a microcirculation microscope (Manufacturer: Xuzhou Tongren Medical Electronic Technology Co., Ltd; Model: tr8000).The Vaginal Health Scale (VHS) [11] was used to evaluate the vaginal health status of patients into five factors: pH, discharge, vaginal elasticity, moisture, and vaginal mucosa. The total score is 20 points. The higher the score, the healthier the vagina.Quality of life after the intervention was assessed according to theGeneral Quality of Life Inventory 74 (GQOLI-74) [12], which scores four aspects of psychological functioning, physical functioning, social functioning, and physical living status. The total score is 100 points. The higher the score, the better the quality of life.Recurrence was recorded in both groups at a 3-month follow-up observation after treatment.


## 2.6. Statistical Analysis

All data analysis was done by SPSS20.0, and the graphics were plotted by GraphPad Prism 7 (GraphPad Software, San Diego, USA). The counting data and measurement data were examined byχ2 test, t-test, and normality test. A P value of 0.05 or lower was claimed as statistically significant.


## 3. Results

### 3.1. General Information

No significant difference in age, BMI, courses, SAS score, SDS score, disease manifestation, and residence of the two groups was found as shown in Table1.Table 1
Comparison of the general information.
Experimental group (n = 45)Control group (n = 45)χ2 or tPAge (years)1.5500.12530.25 ± 3.3231.33 ± 3.29BMI (kg/m2)1.1190.26626.27 ± 1.5925.89 ± 1.63Course (d)0.0410.96834.12 ± 1.2134.13 ± 1.11SAS (scores)1.5330.12947.33 ± 0.5147.17 ± 0.48SDS (scores)0.2580.79752.13 ± 1.6152.21 ± 1.32Disease manifestationPruritus vulvae28 (62.22)25 (55.56)0.4130.520Leucorrhea increases11 (24.44)13 (28.89)0.2270.634Leucorrhea odor6 (13.33)7 (15.56)0.0890.764Residence0.0500.822City31 (68.89)30 (66.67)Village14 (31.11)15 (33.33)


### 3.2. Comparison of Clinical Effects

The experimental group witnessed a much more remarkable improvement as compared to the control group (P<0.05) after treatment. See Table 2.Table 2
Comparison of clinical effects (n (%)).
GroupsNRemarkably effective rateEffective rateInvalid rateTotal effective rateExperimental group4566.67% (30/45)31.11% (14/45)2.22% (1/45)97.78% (44/45)Control group4546.67% (21/45)26.67% (12/45)26.67% (12/45)73.33% (33/45)x210.879P<0.05


### 3.3. Comparison of the Level of Inflammatory Factors

A significantly lower serum level of inflammatory factors of the experimental group than that of the control group was observed (P<0.05) as shown in Table 3.Table 3
Comparison of the serum level of inflammatory factors (y..x±s).
GroupsnTNF-α (pg/L)IL-8 (ng/mL)IL-1β (ng/mL)Before treatmentAfter treatmentBefore treatmentAfter treatmentBefore treatmentAfter treatmentExperimental group4563.88 ± 9.8919.36 ± 5.274.23 ± 0.521.65 ± 1.8762.13 ± 4.5347.32 ± 3.23Control group4564.01 ± 10.1127.23 ± 7.324.25 ± 0.493.58 ± 2.2761.99 ± 4.8655.27 ± 3.68t0.0875.8530.1884.4020.14110.892P0.931<0.0010.852<0.0010.888<0.001


### 3.4. Comparison of Microcirculation Indexes

Table4 displays that the experimental group experienced a favorable microcirculation index in comparison with the control group (P<0.05).Table 4
Comparison of the serum level of inflammatory factors (y..x±s).
GroupsnBlood flow perfusion (V)Erythrocyte aggregation (%)The diameter of capillary (μm)Before treatmentAfter treatmentBefore treatmentAfter treatmentBefore treatmentAfter treatmentExperimental group450.39 ± 0.051.31 ± 0.2767.88 ± 5.4311.85 ± 1.493.77 ± 0.358.13 ± 0.62Control group450.38 ± 0.020.86 ± 0.1267.52 ± 5.5121.33 ± 2.873.81 ± 0.315.61 ± 0.43t1.24610.2170.31219.6660.57422.405P0.216<0.0010.756<0.0010.568<0.001


### 3.5. Comparison of the VHS Score

A superior VHS score of the experimental group after treatment to the control group was obtained (P<0.001); see Figure 1.Figure 1
Comparison of VHS score (y..x±s). The horizontal axis represents before and after treatment, and the vertical axis represents the VHS score (points). The VHS score of experimental group before and after treatment were (5.11 ± 0.53) and (18.23 ± 1.22), respectively. The VHS score of control group before and after treatment were (5.13 ± 0.49) and (10.32 ± 1.03), respectively. ∗ indicates that the patient’s VHS score of the experimental group significantly increased after treatment (t = 66.167, P<0.001); ∗∗ demonstrates that there was a dramatic promotion of patient’s VHS score of the control group after treatment (t = 30.524, P<0.001); ∗∗∗ displays a remarkable difference of patient’s VHS score in different groups after treatment (t = 33.233, P<0.001).


### 3.6. Comparison of the GQOLI-74 Score

The GQOLI-74 score of the experimental group after treatment was observably higher than that of the control group (P<0.05) as shown in Figure 2.Figure 2
Comparison of GQOLI-74 score (x ± s). The horizontal axis represents before and after treatment, and the vertical axis represents the GQOLI-74 score. The GQOLI-74 score of experimental group before and after treatment were (46.32 ± 5.33) and (83.27 ± 7.24), respectively. The GQOLI-74 score of control group before and after treatment were (46.29 ± 5.41) and (63.28 ± 6.83), separately. ∗ shown that the GQOLI-74 score of experimental group was enhanced obviously after treatment (t = 27.570, P<0.001); ∗∗ exhibits a remarkable increase of patient’s GQOLI-74 score of the control group after treatment (t = 13.081, P<0.001); ∗∗∗ indicates that there is a significant difference of the GQOLI-74 score in the experimental group before and after treatment (13.473, P<0.001).


### 3.7. Comparison of the Recurrence Rate

Figure3 exhibits a remarkable lower recurrence rate in the experimental group 3 months after treatment (P<0.05).Figure 3
Comparison of recurrence rate (n (%)). (a) and (b) represent the recurrence rate of the experimental and control group, respectively. In the experimental group, the recurrence rate was 4.44% (2/45) and the nonrecurrence rate was 95.56% (43/45) 3 months after treatment. In the control group, the recurrence and nonrecurrence rate were 28.89% (13/45) and 71.11% (32/45) 3 months later after treatment, respectively. There was a distinct difference in the recurrence rate between the experimental and control groups (x2 = 9.680, P<0.05).
(a)(b)


## 3.1. General Information

No significant difference in age, BMI, courses, SAS score, SDS score, disease manifestation, and residence of the two groups was found as shown in Table1.Table 1
Comparison of the general information.
Experimental group (n = 45)Control group (n = 45)χ2 or tPAge (years)1.5500.12530.25 ± 3.3231.33 ± 3.29BMI (kg/m2)1.1190.26626.27 ± 1.5925.89 ± 1.63Course (d)0.0410.96834.12 ± 1.2134.13 ± 1.11SAS (scores)1.5330.12947.33 ± 0.5147.17 ± 0.48SDS (scores)0.2580.79752.13 ± 1.6152.21 ± 1.32Disease manifestationPruritus vulvae28 (62.22)25 (55.56)0.4130.520Leucorrhea increases11 (24.44)13 (28.89)0.2270.634Leucorrhea odor6 (13.33)7 (15.56)0.0890.764Residence0.0500.822City31 (68.89)30 (66.67)Village14 (31.11)15 (33.33)


## 3.2. Comparison of Clinical Effects

The experimental group witnessed a much more remarkable improvement as compared to the control group (P<0.05) after treatment. See Table 2.Table 2
Comparison of clinical effects (n (%)).
GroupsNRemarkably effective rateEffective rateInvalid rateTotal effective rateExperimental group4566.67% (30/45)31.11% (14/45)2.22% (1/45)97.78% (44/45)Control group4546.67% (21/45)26.67% (12/45)26.67% (12/45)73.33% (33/45)x210.879P<0.05


## 3.3. Comparison of the Level of Inflammatory Factors

A significantly lower serum level of inflammatory factors of the experimental group than that of the control group was observed (P<0.05) as shown in Table 3.Table 3
Comparison of the serum level of inflammatory factors (y..x±s).
GroupsnTNF-α (pg/L)IL-8 (ng/mL)IL-1β (ng/mL)Before treatmentAfter treatmentBefore treatmentAfter treatmentBefore treatmentAfter treatmentExperimental group4563.88 ± 9.8919.36 ± 5.274.23 ± 0.521.65 ± 1.8762.13 ± 4.5347.32 ± 3.23Control group4564.01 ± 10.1127.23 ± 7.324.25 ± 0.493.58 ± 2.2761.99 ± 4.8655.27 ± 3.68t0.0875.8530.1884.4020.14110.892P0.931<0.0010.852<0.0010.888<0.001


## 3.4. Comparison of Microcirculation Indexes

Table4 displays that the experimental group experienced a favorable microcirculation index in comparison with the control group (P<0.05).Table 4
Comparison of the serum level of inflammatory factors (y..x±s).
GroupsnBlood flow perfusion (V)Erythrocyte aggregation (%)The diameter of capillary (μm)Before treatmentAfter treatmentBefore treatmentAfter treatmentBefore treatmentAfter treatmentExperimental group450.39 ± 0.051.31 ± 0.2767.88 ± 5.4311.85 ± 1.493.77 ± 0.358.13 ± 0.62Control group450.38 ± 0.020.86 ± 0.1267.52 ± 5.5121.33 ± 2.873.81 ± 0.315.61 ± 0.43t1.24610.2170.31219.6660.57422.405P0.216<0.0010.756<0.0010.568<0.001


## 3.5. Comparison of the VHS Score

A superior VHS score of the experimental group after treatment to the control group was obtained (P<0.001); see Figure 1.Figure 1
Comparison of VHS score (y..x±s). The horizontal axis represents before and after treatment, and the vertical axis represents the VHS score (points). The VHS score of experimental group before and after treatment were (5.11 ± 0.53) and (18.23 ± 1.22), respectively. The VHS score of control group before and after treatment were (5.13 ± 0.49) and (10.32 ± 1.03), respectively. ∗ indicates that the patient’s VHS score of the experimental group significantly increased after treatment (t = 66.167, P<0.001); ∗∗ demonstrates that there was a dramatic promotion of patient’s VHS score of the control group after treatment (t = 30.524, P<0.001); ∗∗∗ displays a remarkable difference of patient’s VHS score in different groups after treatment (t = 33.233, P<0.001).


## 3.6. Comparison of the GQOLI-74 Score

The GQOLI-74 score of the experimental group after treatment was observably higher than that of the control group (P<0.05) as shown in Figure 2.Figure 2
Comparison of GQOLI-74 score (x ± s). The horizontal axis represents before and after treatment, and the vertical axis represents the GQOLI-74 score. The GQOLI-74 score of experimental group before and after treatment were (46.32 ± 5.33) and (83.27 ± 7.24), respectively. The GQOLI-74 score of control group before and after treatment were (46.29 ± 5.41) and (63.28 ± 6.83), separately. ∗ shown that the GQOLI-74 score of experimental group was enhanced obviously after treatment (t = 27.570, P<0.001); ∗∗ exhibits a remarkable increase of patient’s GQOLI-74 score of the control group after treatment (t = 13.081, P<0.001); ∗∗∗ indicates that there is a significant difference of the GQOLI-74 score in the experimental group before and after treatment (13.473, P<0.001).


## 3.7. Comparison of the Recurrence Rate

Figure3 exhibits a remarkable lower recurrence rate in the experimental group 3 months after treatment (P<0.05).Figure 3
Comparison of recurrence rate (n (%)). (a) and (b) represent the recurrence rate of the experimental and control group, respectively. In the experimental group, the recurrence rate was 4.44% (2/45) and the nonrecurrence rate was 95.56% (43/45) 3 months after treatment. In the control group, the recurrence and nonrecurrence rate were 28.89% (13/45) and 71.11% (32/45) 3 months later after treatment, respectively. There was a distinct difference in the recurrence rate between the experimental and control groups (x2 = 9.680, P<0.05).
(a)(b)


## 4. Discussions

Trichomoniasis is a common vaginal inflammatory disease caused byTrichomonas vaginalis and is a common sexually transmitted disease characterized by vulvar itching and a foamy, yellowish-white, and thin discharge [1]. The disease is associated with the patient’s physical condition, especially in women around the time of menstruation, when the pH of the vagina changes, making it suitable for trichomonads to grow and multiply, causing inflammatory episodes. Trichomoniasis can lead to infertility if not treated properly or in a timely manner and can be harmful to the psychological and physical health of the patient [2]. Trichomonas vaginitis is characterized by features like high incidence and often accompanied by various diseases such as pruritus vulvae, which can not only trigger negative emotions in patients but also diminish their quality of life [13, 14]. Currently, drug therapy is the main clinical treatment for this disease. Although monotherapy is clinically effective, it can lead to increased drug resistance and relapse rates with prolonged treatment [15–17]. Metronidazole vaginal effervescent tablets are common antibacterial drugs in clinic of trichomonas vaginitis, which can yield an effect by blocking the metabolism of trichomonas and bacteria, promoting their death, so as to achieve the purpose of antibacterial [18, 19]. Kushen suppository, which is composed of lanolin, semisynthetic fatty acids, and total matrine, has both antibacterial and anti-inflammatory effects. In addition, related studies have demonstrated that matrine can improve patient’s body immunity, enhance the phagocytic phagocytosis, and has an obvious effect on inflammatory injury and mucosal repair [20].In this study, the total clinical effective of the experimental group, which was treated with metronidazole vaginal effervescent tablets combined with Kushen suppository, was evidently higher compared with that of the control group (P<0.05), which received metronidazole vaginal effervescent tablets treatment only. The results showed that the combined drug treatment was more effective than single drug treatment. In addition, the vagina, as a female physiological organ, has a unique physiological structure that tends to cause dysbiosis of the vaginal flora, causing various inflammatory reactions and leading to a decrease in vaginal immunity. The results showed that the serum inflammatory factor level was significantly lower in the experimental group than in the control group after treatment (P<0.05), suggesting that metronidazole vaginal effervescent tablets combined with Kushen suppository can mitigate patient’s inflammatory reaction and inhibit the development of the disease, which is conducive to the recovery of patients with vaginal diseases.Vaginal diseases can lead to microcirculatory abnormalities at the site of the patient’s lesion. Blood perfusion, red blood cell aggregation, and capillary diameter are important indicators of local microcirculation [21, 22]. In the current study, microcirculation indicators improved significantly in both groups after treatment. While, the data of experimental group were distinctly better in comparison with that of control group (P<0.05), which may be attributed to the Chinese herb substances in Kushen suppository. Modern pharmacological studies have manifested that matrine in Kushen suppository has antibacterial, anti-inflammatory, diuretic, and liver protective effects, and it can restrain vaginal fungal infection in some degree, simultaneously. Furthermore, this combination therapy can also interfere with microbial sugar metabolism, make the vaginal pH value return to the normal level, improve the vaginal self-purification effect, and help patients to maintain vaginal health for a long time. In addition, in our results, the recurrence rate was significantly lower in the experimental group compared to the control group (P<0.05), which is in line with the findings of Chlebicz et al. (2016) [23]. The study by Chlebicz et al.(2016) reported “3 cases of recurrence in the experimental group, with a recurrence rate of 7.89%, and 10 cases in the control group, with a recurrence rate of 26.32%, x2 = 4.547, P=0.033”, clearly indicating that metronidazole vaginal tablets combined with bitter ginseng alkaloids can inhibit bacterial growth, improve vaginal cleanliness, and reduce recurrence in patients. The combination of metronidazole vaginal effervescent tablets and bitter ginseng alkaloids clearly demonstrated that metronidazole vaginal effervescent tablets inhibited bacterial growth, improved vaginal cleanliness, improved vaginal environment, and reduced the recurrence rate of patients.In TCM, trichomoniasis is mainly considered to be caused by a deficiency of the spleen and dampness, resulting in damp-heat downward injection, or a deficiency of the liver and kidneys, resulting in increased vulvar discharge, vulvar itching, and burning pain [24]. Therefore, the main treatment is to choose drugs that clear heat and detoxify, clear heat and dampness, kill insects, and relieve itching. In addition to the drugs studied in the article, we can also choose Phellodendron Bark, Job’s Tears, Dan Pi, and Serpentine Seed for treatment, which can have a very good effect of dispelling dampness and relieve itching [25]. Meanwhile, the herbs commonly used in the treatment of trichomoniasis are usually chosen for sitz baths and fumigation, which are more effective in killing worms locally and relieving itching, and the above herbs can usually be chosen for boiling water and then sitz baths for about five to three minutes, which can be very effective [26]. Additionally, it is important to take care of personal hygiene and to eat as lightly as possible during treatment [25].However, there are some limitations to our experiments. First, the sample and the scope of our experiment are too small, which may lead to large errors. Second, trichomoniasis requires long-term treatment and the duration of our trial was too short to demonstrate long-term efficacy. Therefore, in a follow-up trial, we will need a large number of follow-up visits to determine long-term efficacy and prognosis.


## 5. Conclusion

In conclusion, for patients with trichomonas vaginitis, metronidazole vaginal effervescent tablets combined with Kushen suppository can engender an outstanding effect in ameliorating the vaginal environment, abating the recurrence rate, repressing inflammatory reaction, and improving the quality of life, which is worthy of promotion and application.



---

*Source: 7730474-2022-07-12.xml*